Loading…
CytomX Therapeutics, Inc. is projected to rise to $4.34 by 2027, a +14% move from its current price of $3.81. CTMX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.71 | $3.81 | $3.92 | +0.02% |
| May 30 | $3.66 | $3.81 | $3.97 | +0.03% |
| May 31 | $3.63 | $3.81 | $4.00 | +0.05% |
| Jun 1 | $3.61 | $3.81 | $4.03 | +0.07% |
| Jun 2 | $3.58 | $3.81 | $4.06 | +0.09% |
| Jun 3 | $3.56 | $3.81 | $4.08 | +0.10% |
| Jun 4 | $3.54 | $3.81 | $4.11 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.54 | $3.81 | $4.11 | +0.12% |
| Week 2 | $3.44 | $3.82 | $4.24 | +0.24% |
| Week 3 | $3.36 | $3.82 | $4.35 | +0.36% |
| Week 4 | $3.30 | $3.83 | $4.44 | +0.48% |
| Week 5 | $3.25 | $3.83 | $4.52 | +0.60% |
| Week 6 | $3.20 | $3.84 | $4.60 | +0.72% |
| Week 7 | $3.16 | $3.84 | $4.67 | +0.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that concentrates on developing potent biologics to treat the tumor microenvironment. The company uses a conditional activation platform for oncology biologics research and development, including validating targets for antibody-drug conjugates (ADCs), opening therapeutic windows for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators such as cytokines.
Its PROBODY platform is in preclinical research outside oncology. Its development pipeline comprises CX-904, CX-2051, CX-801, CX-2029, and BMS-986288. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, and a clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
The company was founded in 2008 and is based in South San Francisco, California.
CTMX is CytomX Therapeutics, Inc., currently trading at $3.76 with a market cap of $818.56M and a rank of 2675. The stock’s near-term technicals show a neutral stance, with a 30-day range of $3.11 to $4.54 and a current price around $3.76.
A major floor 29.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 28.3% above — a clean break opens room to run.
A major ceiling 77.2% above — clearing it would confirm fresh momentum.
Key CTMX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTMX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.75 | Buy | $3.75 | Buy |
| MA 10 | $3.71 | Buy | $3.77 | Buy |
| MA 20 | $3.88 | Sell | $3.90 | Sell |
| MA 50 | $4.26 | Sell | $4.22 | Sell |
| MA 100 | $4.73 | Sell | $4.31 | Sell |
| MA 200 | $3.97 | Sell | $3.92 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.89 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -26.71 | Neutral |
| Williams %R (14) | -38.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -4.27 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 62.00 | Neutral |
| TRIX (15) | -0.70 | Sell |
| Awesome (5,34) | -0.40 | Sell |
| Ultimate (7,14,28) | 52.99 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 3.78 | Buy |
| ADX (14) | 22.26 | Sell |
| ATR (14) | 0.10 | Info |
The sentiment is NEUTRAL and the RSI14 sits at 40. The stock trades below both the SMA50 of $4.34 and the SMA200 of $3.95, suggesting limited near-term upside. The immediate support is $3.50 and resistance is at $4.89, outlining a defined near-term trading band. The 30-day range runs from $3.11 to $4.54, framing the current activity.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.50 | $3.81 | $5.24 | 0% | Neutral | |
| $3.43 | $4.34 | $5.81 | +14% | Neutral | |
| $3.24 | $4.21 | $5.84 | +10% | Neutral | |
| $3.57 | $4.75 | $6.80 | +25% | Bullish | |
| $3.55 | $4.83 | $7.07 | +27% | Bullish | |
| $3.63 | $5.02 | $7.52 | +32% | Bullish | |
| $4.53 | $6.38 | $9.74 | +68% | Bullish | |
| $4.89 | $7.00 | $10.87 | +84% | Bullish | |
| $4.99 | $7.27 | $11.47 | +91% | Bullish | |
| $5.05 | $7.47 | $11.96 | +96% | Bullish | |
| $7.04 | $11.15 | $19.01 | +193% | Bullish | |
| $10.46 | $18.66 | $34.85 | +390% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.50 | $3.81 | $4.50 | +0.00% |
| June 2026 | $3.32 | $3.90 | $4.69 | +2.39% |
| July 2026 | $3.27 | $3.87 | $4.72 | -0.79% |
| August 2026 | $3.33 | $3.97 | $4.89 | +2.55% |
| September 2026 | $3.44 | $4.13 | $5.14 | +4.11% |
| October 2026 | $3.42 | $4.12 | $5.17 | -0.17% |
| November 2026 | $3.35 | $4.06 | $5.13 | -1.52% |
| December 2026 | $3.39 | $4.13 | $5.24 | +1.58% |
Click any year to see its month-by-month CTMX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CTMX could reach as high as $5.24, with a base case around $3.81 and support toward $3.50 — roughly 0% from $3.81. A consolidation phase looks the most probable path here.
Expect CTMX to range from $3.43 to $5.81 through 2027. The $4.34 average target implies a +14% move from current prices. That is up +14% on the projected 2026 average. Price action looks broadly range-bound.
The CTMX price prediction for 2028 points to an average of $4.21 (low $3.24, high $5.84) — a potential gain of +10% on today's $3.81. A consolidation phase looks the most probable path here.
In 2029, CTMX is projected to trade between $3.57 and $6.80, averaging $4.75 — a potential gain of +25% from today's $3.81. That is up +13% on the projected 2028 average. Momentum favours further upside here.
CytomX Therapeutics, Inc.'s 2030 outlook centres on $4.83, within a $3.55 to $7.07 range. That is up +2% on the projected 2029 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, CTMX could reach as high as $7.52, with a base case around $5.02 and support toward $3.63 — roughly +32% from $3.81. Momentum favours further upside here.
Expect CTMX to range from $4.53 to $9.74 through 2032. The $6.38 average target implies a +68% move from current prices. That is up +27% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The CTMX price prediction for 2033 points to an average of $7.00 (low $4.89, high $10.87) — a potential gain of +84% on today's $3.81. Momentum favours further upside here.
In 2034, CTMX is projected to trade between $4.99 and $11.47, averaging $7.27 — a potential gain of +91% from today's $3.81. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
CytomX Therapeutics, Inc.'s 2035 outlook centres on $7.47, within a $5.05 to $11.96 range. That is up +3% on the projected 2034 average. That marks a +96% change versus current levels. Momentum favours further upside here.
By 2040, CTMX could reach as high as $19.01, with a base case around $11.15 and support toward $7.04 — roughly +193% from $3.81. Buyers look set to stay in control over this stretch.
Expect CTMX to range from $10.46 to $34.85 through 2050. The $18.66 average target implies a +390% move from current prices. That is up +67% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CTMX today (≈ 262.467192 CTMX) could be worth
$4,898.36
+$3,898.36 (+390%) by 2050 · US Dollar
Based on the average projected CTMX price of $18.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTMXwould be worth at today's price.
$1,000 invested in CTMX on May 27, 2025 (≈ 470.588235 CTMX) would be worth
$1,792.94
+$792.94 (+79.3%) today · 1.79× · US Dollar
Based on a CTMX entry price of $2.13 vs. today's $3.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.72 | $1,024.19 | +2.4% |
| 1 month ago | $4.29 | $888.11 | -11.2% |
| 3 months ago | $5.48 | $695.26 | -30.5% |
| 6 months ago | $4.28 | $890.19 | -11.0% |
| 1 year ago | $2.13 | $1,792.94 | +79.3% |
| All time (5.0y) ago | $6.86 | $555.8 | -44.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTMX forecast.
Our base-case forecast reaches $7.60 around 2040.
Implied market cap at $7.60: $1.65B
The multi-year forecast points to a bullish trajectory beyond 2026, with rising averages and higher ROIs over time. The 2026 forecast shows an average of $3.76 and a min of $3.50 with a max of $5.21, while 2027 projects an average of $4.27 and a max of $5.75 (min $3.37). The 2028 projection is $4.16 (max $5.80, min $3.19), and 2029 is $4.73 (max $6.80, min $3.54), as sentiment remains NEUTRAL to BULLISH in the near term.
By 2030 the average reaches $4.76 with a max of $7.01 and a min of $3.49, yielding a ROI of 26.5. The progression continues through 2031 with an average of $4.97, 2032 with $6.41, 2033 with $6.96, 2034 with $7.22, and 2035 with $7.48, all described as BULLISH. By 2040 the average is $11.19 with a ROI of 197.5, and by 2050 the average reaches $18.68 with a ROI of 396.9.
The longer horizon thus shows a clearly bullish backdrop, albeit with inherent uncertainty and the usual caveat that these are estimates, not guarantees.
Tap a question to reveal the answer.
Average $4.76; Min $3.49; Max $7.01; ROI 26.5; sentiment BULLISH.
Yes—the forecast max for 2033 is $10.89; avg $6.96; ROI 85.2; sentiment BULLISH.
Forecasts show bullish sentiment from 2029 onward with rising averages to $18.68 by 2050 and ROI up to 396.9; these are estimates, not guarantees.
Avg $11.19; ROI 197.5.
Avg $18.68; ROI 396.9.
CytomX Therapeutics, Inc. Community Discussion
0Share your CytomX Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.